Shots:

• Samsung Biologics to offer CDO services from cell line development- process development- non-clinical & clinical material manufacturing- to IND submission for global clinical trials of STM418
• The companies have signed their second CDO agreement following the first signed CDO immunology partnership for STT-003 in Mar 2020. The focus of the agreement is to get IND approval further evaluating the candidate in global clinical trials to prove the enhanced efficacy vs existing PD-1 Abs
• STM418 is a mAb that selectively masks glycosylation site N58 on PD-1 that inhibits PD-1/PD-L1 binding to enhance anti-tumor immunity

Click here to read full press release/ article | Ref: Samsung Biologics | Image: Twitter